arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Biofrontera Inc.

BFRI
$1.26 ▲ +0.01 (+0.80%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
25 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Biofrontera Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $14.7M
Dividend Yield
Revenue Growth 17.4%
Op. Margin -42.8%
ROIC -56.2%
FCF / Share $-0.01
Trailing P/E
Price / Book 2.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.08M
↑ +17.4%
Net Income Profit after all expenses
$-4.75M
↓ -13.1%
Operating Margin Operating profit as % of sales
-42.8%
↓ -260.7% 8th
FCF / Share Free cash flow per share
$-0.01
↑ +98.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
8
Returns
9
Financial Health
3
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 25 quarters